Abstract
Neurodegenerative disorders are a result of continuous deterioration of the structure and function of neurons, involving the death of neurons. Neurodegenerative disorders affect millions of people around the world. Several conventional drug delivery strategies are available to treat neurological disorders. However, they are unable to provide adequate cytoarchitecture restoration and connection patterns due to lower solubility, poor bioavailability, drug resistance and incapability to traverse the blood-brain barrier (BBB). Therefore, designing and developing new and efficient delivery systems, that can bring drugs to CNS and have good bioavailability in the brain is very important. Nano drug delivery system acts as a ray of hope in the diagnosis and treatment of neurological disorders. The use of nanomedicines encapsulating therapeutic molecules may enhance transport of drug across BBB, absorption of drug and its controlled release in the human body with minimum adverse effects. This review article includes a comprehensive overview of the BBB, recent developments and application of nanomedicines, including liposomes, nanoparticles, nanomicelles, carbon nanotubes, etc., to the management as well as clinical therapy of various neurodegenerative disorders.
Keywords: Nanomedicines, neurological disorder, nanoparticles, nanocrystals, neurodegenerative disorders, central nervous system.
Combinatorial Chemistry & High Throughput Screening
Title:Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders
Volume: 24 Issue: 10
Author(s): Shobhit Kumar*, Priyanka Singh, Shrestha Sharma, Faheem H. Pottoo, Javed Ali and Sanjula Baboota
Affiliation:
- Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET) NH-58, Delhi- Roorkee Highway, Meerut-250005, Uttar Pradesh,India
Keywords: Nanomedicines, neurological disorder, nanoparticles, nanocrystals, neurodegenerative disorders, central nervous system.
Abstract: Neurodegenerative disorders are a result of continuous deterioration of the structure and function of neurons, involving the death of neurons. Neurodegenerative disorders affect millions of people around the world. Several conventional drug delivery strategies are available to treat neurological disorders. However, they are unable to provide adequate cytoarchitecture restoration and connection patterns due to lower solubility, poor bioavailability, drug resistance and incapability to traverse the blood-brain barrier (BBB). Therefore, designing and developing new and efficient delivery systems, that can bring drugs to CNS and have good bioavailability in the brain is very important. Nano drug delivery system acts as a ray of hope in the diagnosis and treatment of neurological disorders. The use of nanomedicines encapsulating therapeutic molecules may enhance transport of drug across BBB, absorption of drug and its controlled release in the human body with minimum adverse effects. This review article includes a comprehensive overview of the BBB, recent developments and application of nanomedicines, including liposomes, nanoparticles, nanomicelles, carbon nanotubes, etc., to the management as well as clinical therapy of various neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Kumar Shobhit *, Singh Priyanka , Sharma Shrestha , Pottoo H. Faheem , Ali Javed and Baboota Sanjula , Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders, Combinatorial Chemistry & High Throughput Screening 2021; 24 (10) . https://dx.doi.org/10.2174/1386207323666201217151132
DOI https://dx.doi.org/10.2174/1386207323666201217151132 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design IAPs, their Antagonists and their Role in Neurological Disease and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Subject Index To Volume 9
Current Medicinal Chemistry Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy Synthesis and Antiacetylcholinesterase Activity Evaluation of New 2-aryl Benzofuran Derivatives
Letters in Drug Design & Discovery Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Parkinson Disease Genetics: A "Continuum" from Mendelian to Multifactorial Inheritance
Current Molecular Medicine Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine One-pot Synthesis of Dihydropyrano[2,3-c]chromenes via a Three-component Reaction in Aqueous Media
Combinatorial Chemistry & High Throughput Screening Structural and Molecular Basis of Carbohydrate-Protein Interaction Systems as Potential Therapeutic Targets
Current Pharmaceutical Design Structure Diversity, Synthesis, and Biological Activity of Cyathane Diterpenoids in Higher Fungi
Current Medicinal Chemistry Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry SUBJECT INDEX TO VOLUME 1
Current Genomics Patent Selections
Recent Patents on Biomarkers New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients
Current Alzheimer Research